PolyPeptide Group (PPGN) H1 2024 earnings summary

Executive summary

• Achieved solid progress in H1 2024, with EBITDA improving to EUR 2.9 million from EUR -19.4 million in H1 2023, driven by operational improvements and a favorable product mix, and positive operating cash flow.

• Upgraded 2024 guidance to high single-digit revenue growth and a positive mid-single digit EBITDA margin, reflecting strong H1 results and momentum into H2.

• Strategy focuses on innovation, superior development capabilities, and modular capacity expansion, targeting GLP-1 market opportunities and transformation into a leading peptide CDMO.

• Midterm outlook targets doubling 2023 revenues by 2028 and expanding EBITDA margin from -1.8% in 2023 to nearly 25% by 2028.

• Organization strengthened with new leadership appointments, including a new Chief Commercial Officer and focus on green chemistry.

Financial highlights

• H1 2024 revenue rose 2.4% year-over-year to EUR 135.0 million; commercial revenue up 8.6%, development revenue down 5.1%.

• EBITDA for H1 2024 was EUR 2.9 million (2.1% margin), a turnaround from -EUR 19.4 million (-14.7%) in H1 2023, driven by operational efficiency and higher asset utilization.

• Operating cash flow improved from -EUR 48.3 million in H1 2023 to breakeven or EUR 0.5 million in H1 2024.

• CapEx in H1 2024 was about EUR 20 million (15% of revenues), supporting capacity expansion in multiple sites.

• Cash and cash equivalents at end of H1 2024 were EUR 48.5 million.

Outlook and guidance

• 2024 guidance upgraded to high single-digit sales growth and mid-single digit EBITDA margin, with continued net loss expected.

• No changes to CapEx or net result guidance for 2024; CapEx for 2024 guided at EUR 60–70 million.

• Midterm targets: double 2023 revenue by 2028 and approach 25% EBITDA margin, supported by commercial contracts and capacity expansion.

• CapEx investment of 15%-20% of revenues planned from 2025-2028, aligned with customer projects.